Menu Search
Equities

Titan Pharmaceuticals Inc

TN70:MUN

Titan Pharmaceuticals Inc

Actions
  • Price (EUR)7.48
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-36.07%
  • Beta--
Data delayed at least 15 minutes, as of Jan 08 2024 07:03 GMT.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

  • Revenue in USD (TTM)87.00k
  • Net income in USD-4.95m
  • Incorporated1992
  • Employees4.00
  • Location
    Titan Pharmaceuticals IncSUITE 505, 400 OYSTER POINT BLVDSAN FRANCISCO 94080United StatesUSA
  • Phone+1 (415) 244-4990
  • Fax+1 (650) 244-4956
  • Websitehttps://www.titanpharm.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.